A Study of EDG-5506 in Children With Duchenne Muscular Dystrophy (LYNX)

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

76

Participants

Timeline

Start Date

October 24, 2022

Primary Completion Date

February 28, 2026

Study Completion Date

February 28, 2026

Conditions
Duchenne Muscular Dystrophy
Interventions
DRUG

Sevasemten Dose 1

Sevasemten is administered orally once per day

DRUG

Sevasemten Dose 2

Sevasemten is administered orally once per day

DRUG

Sevasemten Dose 3

Sevasemten is administered orally once per day

DRUG

Sevasemten Dose 4

Sevasemten is administered orally once per day

DRUG

Sevasemten Dose 5

Sevasemten is administered orally once per day

DRUG

Placebo

Placebo is administered orally once per day

Trial Locations (14)

21205

Kennedy Krieger Institute, Baltimore

30329

Rare Disease Research, Atlanta

32610

University of Florida, Gainesville

43205

Nationwide Children's Hospital, Columbus

45229

Cincinnati Children's Hospital, Cincinnati

52242

University of Iowa, Iowa City

63110

Washington University School of Medicine, St Louis

66160

University of Kansas Medical Center, Kansas City

72202

Arkansas Children's Hospital, Little Rock

76104

Cook Children's Medical Center, Fort Worth

80045

Children's Hospital Colorado, Aurora

90095

UCLA Medical Center, Los Angeles

95817

UC Davis Medical Center, Sacramento

01605

University of Massachusetts Memorial Medical Center, Worcester

Sponsors
All Listed Sponsors
lead

Edgewise Therapeutics, Inc.

INDUSTRY